March 01, 2015

2015 BIVI PRRS Research Awards Announced at AASV Conference

Company marks $1 million in PRRS research contributions over last 12 years

The threat from new or evolving swine diseases reminds producers and veterinarians of the critical role ongoing research plays in helping find solutions to problems that reduce production and profitability. When it comes to porcine reproductive and respiratory syndrome (PRRS), time has proven there are no easy, simple or quick solutions.

For the past 12 years, the Boehringer Ingelheim Vetmedica, Inc. (BIVI), Advancement in PRRS Research Awards has recognized and supported those who provide practical approaches to manage the disease.

Recently at the American Association of Swine Veterinarians (AASV) Conference in Orlando, BIVI announced the three recipients of its 2015 PRRS Research Awards.  Including the three research awards for this year, the company has contributed nearly $1 million to fund 40 separate PRRS research projects.

“By implementing the key learnings from the research funded by the PRRS Research Award, producers and veterinarians can more effectively stabilize their herds and manage the disease with less impact on production,” says PRRS Research Review Board member Montse Torremorell, DVM, Ph.D. with the University of Minnesota.

Over the years, the BIVI sponsored PRRS Research Awards have been critical in the development of less costly, more reliable diagnostic testing and sampling processes, as well as identifying more effective biosecurity, risk assessment and vaccination strategies.

This year, BIVI awarded a total of $75,000 to support three separate projects by independent swine disease researchers and practitioners.

From the many PRRS research proposals submitted for the 2015 awards consideration, the three following award recipients were selected and recognized at the March AASV Conference in Orlando:

Dr. Robert Morrison, DVM, Ph.D., University of Minnesota – A research project to evaluate the impact of PRRSv immune status at time of infection on time to stability (TTS) and time to baseline production (TTBP) in infected sow herds.

Dr. Beatriz Martinez Lopez, DVM, Ph.D., University of California, Davis – A study to evaluate the role of direct (i.e. animal contact) and indirect (i.e. airborne) transmission of different PRRSv genotypes within and between different swine production systems in the US.

Dr. Laura Greiner, Ph.D., M.S., Carthage Innovative Swine Solutions – A study to understand the actions and implications of people during unloading at lairage on PRRS/PEDV contamination of swine transportation equipment.

The three research proposals were selected based on established criteria that included potential for economic impact to the swine industry; originality and scientific quality; and probability of success in completing the study.     

In addition to Torremorell, members of the PRRS Research Review Board included: Bill Mengeling, DVM, Ph.D., Iowa State University/NADC (retired), Ames, Iowa,; Tim Loula, DVM, Swine Vet Center, St. Peter, MN; Luc Dufresne, DVM, Seaboard Foods, Shawnee Mission, KS; Daryl Olsen, DVM, Audubon-Manning Veterinary Clinic, Audubon, Iowa;, and AASV President Elect Ron Brodersen, DVM, Whole Hog Health Center, Hartington, NE.

Proposal entries for the 2016 Advancement in PRRS Research Awards are due January 1, 2016. For more information, visit PRRSresearch.com.

About Boehringer Ingelheim Vetmedica, Inc.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets.  BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH.  Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.

For more information please visit www.bi-vetmedica.com

Media Contact

Rene Ward

Director, U.S. Animal Health Communications
3902 Gene Field Road
St. Joseph, Missouri 64506